Drug profile

The FDA adverse-event record for Electrolytes

41 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Electrolytes. Species, reactions, and outcomes follow.

#1237 of 2,679
by report volume (all drugs)
41
adverse-event reports
53.7%
death-coded share
Dog
most-reported species
Verify with FDA CVM →

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Electrolytes ranks #1235 of 2679 by total reports (41). Death-coded-share rank requires at least 50 reports. National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1)
97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1)
#1235
This drug, reports of 2679

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Electrolytes has 41 reports now versus 41 in that prior snapshot: 0 the same number of (0.0%).

Report change
+0
Death-coded reports
+0
Death-coded share
+0.0 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Electrolytes changes

Signature read: Electrolytes's 53.7% death-coded share is among the highest in the openFDA drug corpus.

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
41
Total Reports
22
Deaths Reported
53.7%
Death-coded share of reports

Active Ingredients

Electrolytes

Administration Routes

UnknownOralIntravenousSubcutaneous

Species Affected

Dog 22
Cat 10
Horse 7
Cattle 2

Most Affected Breeds

Retriever - Labrador 6
Domestic Shorthair 4
Mixed (Dog) 2
Shepherd Dog - German 2
Maltese 2
Retriever - Golden 2
Domestic Mediumhair 2
Abyssinian cat 1
Arab 1
Quarter Horse 1

Most Reported Reactions

Lethargy (see also Central nervous system depression in 'Neurological') 15
Death 13
Vomiting 9
Anorexia 9
Death by euthanasia 8
Anaemia NOS 7
Weight loss 7
Seizure NOS 6
Depression 6
Elevated total bilirubin 6
Behavioural disorder NOS 5
Pale mucous membrane 5

Outcome Breakdown

Died
14 (34.1%)
Ongoing
9 (22.0%)
Euthanized
8 (19.5%)
Recovered/Normal
7 (17.1%)
Outcome Unknown
3 (7.3%)

Electrolytes: high death-coded share in the FDA AER row

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

What to do with this drug

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Electrolytes (#1237 of 2,679 by report volume); death-coded 53.7%. PlainBreed drug row · death-coded share stamp 53.7% · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →